<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="review-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">cardiovascular</journal-id><journal-title-group><journal-title xml:lang="ru">Кардиоваскулярная терапия и профилактика</journal-title><trans-title-group xml:lang="en"><trans-title>Cardiovascular Therapy and Prevention</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1728-8800</issn><issn pub-type="epub">2619-0125</issn><publisher><publisher-name>«SILICEA-POLIGRAF» LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.15829/1728-8800-2023-3551</article-id><article-id custom-type="elpub" pub-id-type="custom">cardiovascular-3551</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОБЗОРЫ ЛИТЕРАТУРЫ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>REVIEW ARTICLES</subject></subj-group></article-categories><title-group><article-title>Циркулирующие биологические маркеры ожирения: на пути к системному подходу</article-title><trans-title-group xml:lang="en"><trans-title>Circulating biological markers of obesity: towards a systems approach</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9305-6713</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Тимофеев</surname><given-names>Ю. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Timofeev</surname><given-names>Yu. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Тимофеев Юрий Сергеевич — кандидат медицинских наук, старший научный сотрудник отдела фундаментальных и прикладных отделов ожирения.</p><p>Москва</p></bio><bio xml:lang="en"><p>Moscow</p></bio><email xlink:type="simple">timofeev_lab@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5384-3795</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Джиоева</surname><given-names>О. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Dzhioeva</surname><given-names>O. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Джиоева Ольга Николаевна — доктор медицинских наук, ведущий научный сотрудник отдела фундаментальных и прикладных отделов ожирения.</p><p>Москва</p></bio><bio xml:lang="en"><p>Moscow</p></bio><email xlink:type="simple">ODzhioeva@gnicpm.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4453-8430</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Драпкина</surname><given-names>О. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Drapkina</surname><given-names>O. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Драпкина Оксана Михайловна — доктор медицинских наук, профессор, академик РАН, директор.</p><p>Москва</p></bio><bio xml:lang="en"><p>Moscow</p></bio><email xlink:type="simple">ODrapkina@gnicpm.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru">ФГБУ "Национальный медицинский исследовательский центр терапии и профилактической медицины" Минздрава России<country>Россия</country></aff><aff xml:lang="en">National Medical Research Center for Therapy and Preventive Medicine<country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2023</year></pub-date><pub-date pub-type="epub"><day>09</day><month>05</month><year>2023</year></pub-date><volume>22</volume><issue>4</issue><fpage>3551</fpage><lpage>3551</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Тимофеев Ю.С., Джиоева О.Н., Драпкина О.М., 2023</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="ru">Тимофеев Ю.С., Джиоева О.Н., Драпкина О.М.</copyright-holder><copyright-holder xml:lang="en">Timofeev Y.S., Dzhioeva O.N., Drapkina O.M.</copyright-holder><license license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://cardiovascular.elpub.ru/jour/article/view/3551">https://cardiovascular.elpub.ru/jour/article/view/3551</self-uri><abstract><p>В основе патологических процессов, ассоциированных с ожирением, лежит нарушение энергетического гомеостаза, а также избыточная эндокринная и паракринная активность жировой ткани, приводящая к воспалительным реакциям и гормональным дисфункциям, что сопровождается секрецией широкого спектра соединений, оказывающих влияние на ключевые процессы в человеческом организме. Одним из косвенных методов оценки происходящих в жировой ткани изменений является измерение концентраций циркулирующих соединений, включая цитокины, факторы роста, а также класса специфических соединений — адипокинов, специфичных для жировой ткани. Исследование циркулирующих биомаркеров позволяет прослеживать их связь с риском осложнений, метаболическим вариантом ожирения и другими клиническими и функциональными особенностями. К подобным маркерам можно отнести адипокины (лептин, адипонектин, апелин, резистин, оментин, висфатин, хемерин, липокалин и др.), биомаркеры воспаления, белки теплового шока, которые подробно рассматриваются в данном обзоре в контексте их применения при ожирении и сопутствующих нозологиях.</p></abstract><trans-abstract xml:lang="en"><p>The pathological processes associated with obesity are based on impaired energy homeostasis, as well as excessive endocrine and paracrine activity of adipose tissue, leading to inflammation and hormonal imbalance, which is accompanied by the secretion of a wide range of compounds affecting key body processes. One of the indirect methods for assessing the adipose tissue abnormalities is the measurement of the concentration of cytokines, growth factors, as well as a class of specific compounds — adipokines specific to adipose tissue. The study of circulating biomarkers makes it possible to assess their association with the risk of complications, metabolic obesity, and other clinical and functional features. Such markers include adipokines (leptin, adiponectin, apelin, resistin, omentin, visfatin, chemerin, lipocalin, etc.), inflammation biomarkers, heat shock proteins, which are discussed in detail in this review in the context of their use in obesity and concomitant diseases.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>ожирение</kwd><kwd>воспаление</kwd><kwd>биомаркеры</kwd><kwd>адипокины</kwd><kwd>цитокины</kwd><kwd>белки теплового шока</kwd></kwd-group><kwd-group xml:lang="en"><kwd>obesity</kwd><kwd>inflammation</kwd><kwd>biomarkers</kwd><kwd>adipokines</kwd><kwd>cytokines</kwd><kwd>heat shock proteins</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Драпкина О. М., Самородская И. В., Старинская М. А. и др. Ожирение: оценка и тактика ведения пациентов. М.: ФГБУ "НМИЦ ТПМ" Минздрава России, 2021. с. 174. ISBN: 978-5-9907556-0-4.</mixed-citation><mixed-citation xml:lang="en">Drapkina OM, Samorodskaia IV, Starinskaia MA, et al. Obesity: evaluation and management of patients. M.: NMRC TPM Russian Ministry of Health, 2021. p. 174. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Schulze MB. Metabolic health in normal-weight and obese individuals. Diabetologia. 2019;62(4):558-66. doi:10.1007/s00125-018-4787-8.</mixed-citation><mixed-citation xml:lang="en">Schulze MB. Metabolic health in normal-weight and obese individuals. Diabetologia. 2019;62(4):558-66. doi:10.1007/s00125-018-4787-8.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Kouvari M, Panagiotakos DB, Yannakoulia M, et al. Transition from metabolically benign to metabolically unhealthy obesity and 10-year cardiovascular disease incidence: The ATTICA cohort study. Metabolism. 2019;93:18-24. doi:10.1016/j.metabol.2019.01.003.</mixed-citation><mixed-citation xml:lang="en">Kouvari M, Panagiotakos DB, Yannakoulia M, et al. Transition from metabolically benign to metabolically unhealthy obesity and 10-year cardiovascular disease incidence: The ATTICA cohort study. Metabolism. 2019;93:18-24. doi:10.1016/j.metabol.2019.01.003.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Scheja L, Heeren J. The endocrine function of adipose tissues in health and cardiometabolic disease. Nat Rev Endocrinol. 2019;15:507-24. doi:10.1038/s41574-019-0230-6.</mixed-citation><mixed-citation xml:lang="en">Scheja L, Heeren J. The endocrine function of adipose tissues in health and cardiometabolic disease. Nat Rev Endocrinol. 2019;15:507-24. doi:10.1038/s41574-019-0230-6.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Paillaud E, Poisson J, Granier C, et al. Serum Leptin Levels, Nutritional Status, and the Risk of Healthcare-Associated Infections in Hospitalized Older Adults. Nutrients. 2022;14(1):226. doi:10.3390/nu14010226.</mixed-citation><mixed-citation xml:lang="en">Paillaud E, Poisson J, Granier C, et al. Serum Leptin Levels, Nutritional Status, and the Risk of Healthcare-Associated Infections in Hospitalized Older Adults. Nutrients. 2022;14(1):226. doi:10.3390/nu14010226.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Матосян К. А., Оранская А. Н., Мкртумян А. М. и др. Био­химические маркеры ожирения у лиц 18-25 лет. Кардиовас­кулярная тера­­пия и профилактика. 2017;16(5):34-9. doi:10.15829/1728-8800-2017-5-34-39.</mixed-citation><mixed-citation xml:lang="en">Matosyan KA, Oranskaya AN, Gurevich KG, et al. Biochemical markers of obesity in the 18-25-year-old patients. Cardiovascular Therapy and Prevention. 2017;16(5):34-9. (In Russ.) doi:10.15829/1728-8800-2017-5-34-39.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Трошина Е. А., Комшилова К. А., Ершова Е. В. и др. Ожирение (необходимые лабораторные методы диагностики). Мето­дические рекомендации для врачей первичного звена. Consilium Medicum. 2019;21(12):48-50. doi:10.26442/20751753.2019.12.190680.</mixed-citation><mixed-citation xml:lang="en">Troshina EA, Komshilova KA, Ershova EV, et al. Obesity (essential laboratory diagnostic tests). Guidelines for general medical practitioners. Consilium Medicum. 2019;21(12):48-50. (In Russ.) doi:10.26442/20751753.2019.12.190680.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Корноухова Л. А., Денисов Н. Л., Марченко В. Н. и др. Ранняя диагностика метаболических нарушений функции печени при ожирении. Гастроэнтерология. 2019;8(163):35-43. doi:10.31550/1727-2378-2019-163-8-35-43.</mixed-citation><mixed-citation xml:lang="en">Kornoukhova LA, Denisov NL, Marchenko VN, et al. Early dia­gnosis of hepatic metabolic disorders in obese patients. Gastroenterology. 2019;8(163):35-43. (In Russ.) doi:10.31550/1727-2378-2019-163-8-35-43.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Almabhouh FA, Md Mokhtar AH, Malik IA, et al. Leptin and reproductive dysfunction in obese men. Andrologia. 2020;52(1):e13433. doi:10.1111/and.13433.</mixed-citation><mixed-citation xml:lang="en">Almabhouh FA, Md Mokhtar AH, Malik IA, et al. Leptin and reproductive dysfunction in obese men. Andrologia. 2020;52(1):e13433. doi:10.1111/and.13433.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Zulfania Khan A, Ghaffar T, et al. Correlation between serum leptin level and Body mass index (BMI) in patients with type 2 diabetes Mellitus. J Pak Med Assoc. 2020;70(1):3-6. doi:10.5455/JPMA.301135.</mixed-citation><mixed-citation xml:lang="en">Zulfania Khan A, Ghaffar T, et al. Correlation between serum leptin level and Body mass index (BMI) in patients with type 2 diabetes Mellitus. J Pak Med Assoc. 2020;70(1):3-6. doi:10.5455/JPMA.301135.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Qin Z, Yang Q, Yang M, et al. Serum leptin concentration can predict cardiovascular outcomes and all-cause death in maintenance hemodialysis patients. Clin Chim Acta. 2021;520:87-94. doi:10.1016/j.cca.2021.06.003.</mixed-citation><mixed-citation xml:lang="en">Qin Z, Yang Q, Yang M, et al. Serum leptin concentration can predict cardiovascular outcomes and all-cause death in maintenance hemodialysis patients. Clin Chim Acta. 2021;520:87-94. doi:10.1016/j.cca.2021.06.003.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Peng Y, Yang H, Song J, et al. Elevated Serum Leptin Levels as a Predictive Marker for Polycystic Ovary Syndrome. Front Endocrinol (Lausanne). 2022;13:845165. doi:10.3389/fendo.2022.845165.</mixed-citation><mixed-citation xml:lang="en">Peng Y, Yang H, Song J, et al. Elevated Serum Leptin Levels as a Predictive Marker for Polycystic Ovary Syndrome. Front Endocrinol (Lausanne). 2022;13:845165. doi:10.3389/fendo.2022.845165.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Alatas SE, Yavuz Dogu S, Kilic D, et al. Comparison of serum adiponectin and osteopontin levels along with metabolic risk factors between obese and lean women with and without PCOS. Endokrynol Pol. 2020;71(6):497-503. doi:10.5603/EP.a2020.0074.</mixed-citation><mixed-citation xml:lang="en">Alatas SE, Yavuz Dogu S, Kilic D, et al. Comparison of serum adiponectin and osteopontin levels along with metabolic risk factors between obese and lean women with and without PCOS. Endokrynol Pol. 2020;71(6):497-503. doi:10.5603/EP.a2020.0074.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Kurose S, Onishi K, Takao N, et al. Association of serum adipo­nectin and myostatin levels with skeletal muscle in patients with obesity: A cross-sectional study. PLoS One. 2021;16(1):e0245678. doi:10.1371/journal.pone.0245678.</mixed-citation><mixed-citation xml:lang="en">Kurose S, Onishi K, Takao N, et al. Association of serum adipo­nectin and myostatin levels with skeletal muscle in patients with obesity: A cross-sectional study. PLoS One. 2021;16(1):e0245678. doi:10.1371/journal.pone.0245678.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang Y, Peltonen M, Andersson-Assarsson JC, et al. Elevated adiponectin predicts the development of rheumatoid arthritis in subjects with obesity. Scand J Rheumatol. 2020;49(6):452-60. doi:10.1080/03009742.2020.1753808.</mixed-citation><mixed-citation xml:lang="en">Zhang Y, Peltonen M, Andersson-Assarsson JC, et al. Elevated adiponectin predicts the development of rheumatoid arthritis in subjects with obesity. Scand J Rheumatol. 2020;49(6):452-60. doi:10.1080/03009742.2020.1753808.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Танянский Д. А., Шавва В. С., Диже Э. Б. и др. Адипонектин стимулирует экспрессию гена аполипопротеина А-1 в клетках HepG2 через сигнальные пути AMPK, PPAR-альфа и LXR. Биохимия. 2022;87(11):1700-8. doi:10.31857/S0320972522110148.</mixed-citation><mixed-citation xml:lang="en">Tanyanskiy DA, Shavva VS, Dizhe EB, et al. Adiponectin stimulates apolipoprotein A-1 gene expression in HEPG2 cells via AMPK, PPAR-alpha, and LXR signalling mechanisms. Biochemistry. 2022;87(11):1700-8. (In Russ.) doi:10.31857/S0320972522110148.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">El Wakeel MA, El-Kassas GM, Kamhawy AH, et al. Serum Apelin and Obesity-Related Complications in Egyptian Children. Open Access Maced J Med Sci. 2018;6(8):1354-8. doi:10.3889/oamjms.2018.312.</mixed-citation><mixed-citation xml:lang="en">El Wakeel MA, El-Kassas GM, Kamhawy AH, et al. Serum Apelin and Obesity-Related Complications in Egyptian Children. Open Access Maced J Med Sci. 2018;6(8):1354-8. doi:10.3889/oamjms.2018.312.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Yin C, Zhang H, Zhang M, et al. Adropin and apelin-12 efficiently predict metabolic syndrome in obese children. Pediatr Diabetes. 2020;21(7):1132-9. doi:10.1111/pedi.13101.</mixed-citation><mixed-citation xml:lang="en">Yin C, Zhang H, Zhang M, et al. Adropin and apelin-12 efficiently predict metabolic syndrome in obese children. Pediatr Diabetes. 2020;21(7):1132-9. doi:10.1111/pedi.13101.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Листопад О. В., Баженова Е. А., Ионин В. А. и др. Апелин и ремоделирование сердца у больных абдоминальным ожирением. Учёные записки Первого Санкт-Петербургского государственного медицинского университета имени академика И. П. Павлова. 2015;22(2):17-9. doi:10.24884/1607-4181-2015-22-2-17-19.</mixed-citation><mixed-citation xml:lang="en">Listopad OV, Bazhenova EA, Ionin VA, et al. Apelin and heart remo­deling in patients with abdominal obesity. The Scientific Notes of the Pavlov University. 2015;22(2):17-9. (In Russ.) doi:10.24884/1607-4181-2015-22-2-17-19.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Kollari E, Zografou I, Sampanis C, et al. Serum adipokine levels in patients with type 1 diabetes are associated with degree of obesity but only resistin is independently associated with atherosclerosis markers. Hormones (Athens). 2022;21(1):91-101. doi:10.1007/s42000-021-00328-9.</mixed-citation><mixed-citation xml:lang="en">Kollari E, Zografou I, Sampanis C, et al. Serum adipokine levels in patients with type 1 diabetes are associated with degree of obesity but only resistin is independently associated with atherosclerosis markers. Hormones (Athens). 2022;21(1):91-101. doi:10.1007/s42000-021-00328-9.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Гуссаова С. С., Бобкова И. Н., Ставровская Е. В. и др. Уровень сывороточного резистина и инсулинорезистентность у больных морбидным ожирением. Нефрология. 2019; 23 (приложение 1):78. doi:10.36485/1561-6274-2019-23-5-75-88.</mixed-citation><mixed-citation xml:lang="en">Gussaova SS, Bobkova IN, Stavrovskaya EV, et al. Serum level of resistin and insulin resistance in patients with morbid obesity. Nephrology (Saint-Petersburg) 2019; 23 (supplement 1):78. (In Russ.) Гуссаова С. С., Бобкова И. Н., Ставровская Е. В. и др. Уровень сывороточного резистина и инсулинорезистентность у больных морбидным ожирением. Нефрология. 2019; 23 (приложение 1):78. doi:10.36485/1561-6274-2019-23-5-75-88.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Zengi S, Zengi O, Kirankaya A, et al. Serum omentin-1 levels in obese children. J Pediatr Endocrinol Metab. 2019;32(3):247-51. doi:10.1515/jpem-2018-0231.</mixed-citation><mixed-citation xml:lang="en">Zengi S, Zengi O, Kirankaya A, et al. Serum omentin-1 levels in obese children. J Pediatr Endocrinol Metab. 2019;32(3):247-51. doi:10.1515/jpem-2018-0231.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Xu T, Li Y, Su Y, et al. Serum omentin-1 and risk of one-year mortality in patients with ischemic stroke. Clin Chim Acta. 2020;505:167-71. doi:10.1016/j.cca.2020.03.007.</mixed-citation><mixed-citation xml:lang="en">Xu T, Li Y, Su Y, et al. Serum omentin-1 and risk of one-year mortality in patients with ischemic stroke. Clin Chim Acta. 2020;505:167-71. doi:10.1016/j.cca.2020.03.007.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Драганова А. С., Полякова Е. А., Колодина Д. А. и др. Концент­рация оментина-1 в сыворотке крови у больных ишемической болезнью сердца. Трансляционная медицина. 2019;6(6):5-13. doi:10.18705/2311-4495-2019-6-6-5-13.</mixed-citation><mixed-citation xml:lang="en">Draganova AS, Polyakova EA, Kolodina DA, et al. Concentration omentin-1 in the serum of patients with coronary heart disease. Translational Medicine. 2019;6(6):5-13. (In Russ.) doi:10.18705/2311-4495-2019-6-6-5-13.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Elkabany ZA, Hamza RT, Ismail EAR, et al. Serum visfatin level as a noninvasive marker for nonalcoholic fatty liver disease in children and adolescents with obesity: relation to transient elastography with controlled attenuation parameter. Eur J Gastroenterol Hepatol. 2020;32(8):1008-16. doi:10.1097/MEG.0000000000001608.</mixed-citation><mixed-citation xml:lang="en">Elkabany ZA, Hamza RT, Ismail EAR, et al. Serum visfatin level as a noninvasive marker for nonalcoholic fatty liver disease in children and adolescents with obesity: relation to transient elastography with controlled attenuation parameter. Eur J Gastroenterol Hepatol. 2020;32(8):1008-16. doi:10.1097/MEG.0000000000001608.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Radzicka-Mularczyk S, Zaborowski MP, Brązert J, et al. Serum visfatin as a metabolic biomarker in obese patients with gestational diabetes mellitus. Minerva Endocrinol (Torino). 2021;46(4):396-405. doi:10.23736/S2724-6507.20.03280-0.</mixed-citation><mixed-citation xml:lang="en">Radzicka-Mularczyk S, Zaborowski MP, Brązert J, et al. Serum visfatin as a metabolic biomarker in obese patients with gestational diabetes mellitus. Minerva Endocrinol (Torino). 2021;46(4):396-405. doi:10.23736/S2724-6507.20.03280-0.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Rowicka G, Dyląg H, Chełchowska M, et al. Serum Calprotectin and Chemerin Concentrations as Markers of Low-Grade Inflammation in Prepubertal Children with Obesity. Int J Environ Res Public Health. 2020;17(20):7575. doi:10.3390/ijerph17207575.</mixed-citation><mixed-citation xml:lang="en">Rowicka G, Dyląg H, Chełchowska M, et al. Serum Calprotectin and Chemerin Concentrations as Markers of Low-Grade Inflammation in Prepubertal Children with Obesity. Int J Environ Res Public Health. 2020;17(20):7575. doi:10.3390/ijerph17207575.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Mosialou I, Shikhel S, Luo N, et al. Lipocalin-2 counteracts metabolic dysregulation in obesity and diabetes. J Exp Med. 2020;217(10):e20191261. doi:10.1084/jem.20191261.</mixed-citation><mixed-citation xml:lang="en">Mosialou I, Shikhel S, Luo N, et al. Lipocalin-2 counteracts metabolic dysregulation in obesity and diabetes. J Exp Med. 2020;217(10):e20191261. doi:10.1084/jem.20191261.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Шулькина С. Г., Щекотов В. В., Смирнова Е. Н. и др. Васкулоэндотелиальный фактор роста сосудов и липокалин 2 как маркеры раннего повреждения нефрона у пациентов с гипертонической болезнью и ожирением. Современные технологии в медицине. 2016;8(1):48-52. doi:10.17691/stm2016.8.1.20.</mixed-citation><mixed-citation xml:lang="en">Shulkina SG, Schekotov VV, Smirnova EN, et al. Vascular Endothelial Growth Factor and lipocalin-2 as markers of early nephron damage in patients with hypertension and obesity. Sovremennye tehnologii v medicine. 2016;8(1):48-52. (In Russ.) doi:10.17691/stm2016.8.1.20.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Драпкина О. М., Деева Т. А. Прогностическое значение определения уровня галектина-3 у пациентов с метаболическим синдромом и неалкогольной жировой болезнью печени. Кардиоваскулярная терапия и профилактика. 2015;14(5):40-7. doi:10.15829/1728-8800-2015-5-40-47.</mixed-citation><mixed-citation xml:lang="en">Drapkina OM, Deeva TA. Prognostic significance of galectin-3 measurement in patients with metabolic syndrome and non-alcoholic fatty liver disease. Cardiovascular Therapy and Prevention. 2015;14(5):40-7. (In Russ.) doi:10.15829/1728-8800-2015-5-40-47.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Nimptsch K, Konigorski S, Pischon T. Diagnosis of obesity and use of obesity biomarkers in science and clinical medicine. Metabolism. 2019;92:61-70. doi:10.1016/j.metabol.2018.12.006.</mixed-citation><mixed-citation xml:lang="en">Nimptsch K, Konigorski S, Pischon T. Diagnosis of obesity and use of obesity biomarkers in science and clinical medicine. Metabolism. 2019;92:61-70. doi:10.1016/j.metabol.2018.12.006.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Vandebergh M, Becelaere S. CHARGE Inflammation Working Group; Dubois B, Goris A. Body Mass Index, Interleukin-6 Signaling and Multiple Sclerosis: A Mendelian Randomization Study. Front Immunol. 2022;13:834644. doi:10.3389/fimmu.2022.834644.</mixed-citation><mixed-citation xml:lang="en">Vandebergh M, Becelaere S. CHARGE Inflammation Working Group; Dubois B, Goris A. Body Mass Index, Interleukin-6 Signaling and Multiple Sclerosis: A Mendelian Randomization Study. Front Immunol. 2022;13:834644. doi:10.3389/fimmu.2022.834644.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Alissa EM, Algarni SA, Khaffji AJ, et al. Impact of interlukin-6 on central obesity measures in women with polycystic ovarian syndrome. J Obstet Gynaecol. 2020;40(8):1133-7. doi:10.1080/01443615.2019.1697219.</mixed-citation><mixed-citation xml:lang="en">Alissa EM, Algarni SA, Khaffji AJ, et al. Impact of interlukin-6 on central obesity measures in women with polycystic ovarian syndrome. J Obstet Gynaecol. 2020;40(8):1133-7. doi:10.1080/01443615.2019.1697219.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Pirowska M, Podolec K, Lipko-Godlewska S, et al. Level of inflammatory cytokines tumour necrosis factor α, interleukins 12, 23 and 17 in patients with psoriasis in the context of metabolic syndrome. Postepy dermatologii i alergologii. 2019;36(1):70-5. doi:10.5114/ada.2018.73136.</mixed-citation><mixed-citation xml:lang="en">Pirowska M, Podolec K, Lipko-Godlewska S, et al. Level of inflammatory cytokines tumour necrosis factor α, interleukins 12, 23 and 17 in patients with psoriasis in the context of metabolic syndrome. Postepy dermatologii i alergologii. 2019;36(1):70-5. doi:10.5114/ada.2018.73136.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Alzamil H. Elevated Serum TNF-α Is Related to Obesity in Type 2 Diabetes Mellitus and Is Associated with Glycemic Control and Insulin Resistance. J Obes. 2020;2020:5076858. doi:10.1155/2020/5076858.</mixed-citation><mixed-citation xml:lang="en">Alzamil H. Elevated Serum TNF-α Is Related to Obesity in Type 2 Diabetes Mellitus and Is Associated with Glycemic Control and Insulin Resistance. J Obes. 2020;2020:5076858. doi:10.1155/2020/5076858.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Lazar-Poloczek E, Romuk E, Jachec W, et al. Levels of TNF-α and Soluble TNF Receptors in Normal-Weight, Overweight and Obese Patients with Dilated Non-Ischemic Cardiomyopathy: Does Anti-TNF Therapy Still Have Potential to Be Used in Heart Failure Depending on BMI? Biomedicines. 2022;10(11):2959. doi:10.3390/biomedicines10112959.</mixed-citation><mixed-citation xml:lang="en">Lazar-Poloczek E, Romuk E, Jachec W, et al. Levels of TNF-α and Soluble TNF Receptors in Normal-Weight, Overweight and Obese Patients with Dilated Non-Ischemic Cardiomyopathy: Does Anti-TNF Therapy Still Have Potential to Be Used in Heart Failure Depending on BMI? Biomedicines. 2022;10(11):2959. doi:10.3390/biomedicines10112959.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Gopal DM, Ayalon N, Wang YC, et al. Galectin-3 Is Associated With Stage B Metabolic Heart Disease and Pulmonary Hypertension in Young Obese Patients. J Am Heart Assoc. 2019;8(7):e011100. doi:10.1161/JAHA.118.011100.</mixed-citation><mixed-citation xml:lang="en">Gopal DM, Ayalon N, Wang YC, et al. Galectin-3 Is Associated With Stage B Metabolic Heart Disease and Pulmonary Hypertension in Young Obese Patients. J Am Heart Assoc. 2019;8(7):e011100. doi:10.1161/JAHA.118.011100.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Подзолков В. И., Тарзиманова А. И., Гатаулин Р. Г. и др. Роль ожирения в развитии фибрилляции предсердий: современное состояние проблемы. Кардиоваскулярная терапия и профилактика. 2019;18(4):109-14. doi:10.15829/1728-8800-2019-4-109-114.</mixed-citation><mixed-citation xml:lang="en">Podzolkov VI, Tarzimanova AI, Gataulin RG, et al. The role of obesity in the development of atrial fibrillation: current problem status. Cardiovascular Therapy and Prevention. 2019;18(4):109-14. (In Russ.) doi:10.15829/1728-8800-2019-4-109-114.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Понасенко О. А., Ганковская Л. В., Свитич О. А. Роль белка теплового шока 70 в патогенезе сердечно-сосудистой патологии. Медицинская иммунология. 2019;21(2):201-8. doi:10.15789/1563-0625-2019-2-201-208.</mixed-citation><mixed-citation xml:lang="en">Ponasenko OA, Gankovskaya LV, Svitich OA. The role of the heat shock protein 70 in the pathogenesis of cardiovascular pathology. Medical Immunology (Russia). 2019;21(2):201-8. (In Russ.) doi:10.15789/1563-0625-2019-2-201-208.</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Sell H, Poitou C, Habich C, et al. Heat Shock Protein 60 in Obesity: Effect of Bariatric Surgery and its Relation to Inflammation and Cardiovascular Risk. Obesity (Silver Spring). 2017;25(12):2108-14. doi:10.1002/oby.22014.</mixed-citation><mixed-citation xml:lang="en">Sell H, Poitou C, Habich C, et al. Heat Shock Protein 60 in Obesity: Effect of Bariatric Surgery and its Relation to Inflammation and Cardiovascular Risk. Obesity (Silver Spring). 2017;25(12):2108-14. doi:10.1002/oby.22014.</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Yildirim O, Tatar E. The Roles of Heat Shock Protein-60 and 70 and Inflammation in Obesity-Related Kidney Disease. Cureus. 2022;14(9):e28675. doi:10.7759/cureus.28675.</mixed-citation><mixed-citation xml:lang="en">Yildirim O, Tatar E. The Roles of Heat Shock Protein-60 and 70 and Inflammation in Obesity-Related Kidney Disease. Cureus. 2022;14(9):e28675. doi:10.7759/cureus.28675.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
